Mylan issues nationwide recall for Epipens with defective injectors

Published



Pharmaceuticals company Mylan, which distributes the Epipen, a device for severe allergic reactions, is back in the news.

Mylan on Friday disclosed a possible defect in some of the devices, months after embroiling itself in controversy and a congressional investigation last year by dramatically raising the list price of the life-saving injector to over $600 for a pack of two.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.